循环FABP4是急性缺血性卒中患者的新型预后生物标志物
在中国737例急性缺血性卒中患者中开展前瞻性多中心观察研究,入院时检测血清FABP4浓度,评估其预测3个月功能结局和死亡的价值。随访发现35.3%患者功能结局不良,12.8%死亡;FABP4最高四分位组较参考组不良功能结局和死亡的相对风险为4.77(95%CI 2.02-8.15;P<0.001),且FABP4的AUC分别为0.78和0.83,联合NIHSS评分可提高预后准确性。
要点
- FABP4是急性缺血性卒中3个月不良功能结局和死亡的独立预后标志物
- FABP4最高四分位组不良结局风险显著增高(相对风险4.77,95%CI 2.02-8.15)
- FABP4联合NIHSS评分可提高对功能结局和死亡的预测准确性
核心结论
- FABP4是新型独立预后标志物,可改善卒中患者现有风险分层。
研究设计与样本
- 前瞻性多中心观察研究,纳入737例连续急性缺血性卒中患者。
- 入院时检测血清FABP4浓度,评估其预测3个月功能结局和死亡的价值。
主要发现
- 随访期间260例(35.3%)功能结局不良,94例(12.8%)死亡。
- FABP4最高四分位组较参考组(Q1-Q3)不良功能结局和死亡的相对风险为4.77(95%CI 2.02-8.15;P<0.001),比值比为6.15(95%CI 3.43-12.68)。
- FABP4预测不良功能结局和死亡的AUC分别为0.78(95%CI 0.75-0.82)和0.83(95%CI 0.79-0.88)。
- FABP4联合NIHSS评分的AUC分别为0.83(95%CI 0.76-0.89;P<0.01)和0.86(95%CI 0.81-0.92)。
关键数值与推荐
- FABP4最高四分位组不良功能结局和死亡的相对风险为4.77(95%CI 2.02-8.15;P<0.001)。
- FABP4预测不良功能结局的AUC为0.78(95%CI 0.75-0.82),预测死亡的AUC为0.83(95%CI 0.79-0.88)。
- FABP4联合NIHSS评分预测不良功能结局的AUC为0.83(95%CI 0.76-0.89;P<0.01),预测死亡的AUC为0.86(95%CI 0.81-0.92)。
临床怎么用
- 入院时检测血清FABP4可能有助于急性缺血性卒中患者的预后评估。
- FABP4联合NIHSS评分可提高对3个月功能结局和死亡的预测准确性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: FABP4 (fatty acid-binding protein 4) is an intracellular lipid chaperone involved in coordination of lipid transportation and atherogenesis. This study aimed at observing the effect of FABP4 on the 3-month outcomes in Chinese patients with acute ischemic stroke. METHODS: In a prospective multicenter observational study, serum concentrations of FABP4 were on admission measured in plasma of 737 consecutive patients with acute ischemic stroke. Serum concentrations of FABP4, National Institutes of Health Stroke Scale score, and conventional risk factors were evaluated to determine their value to predict functional outcome and mortality within 3 months. RESULTS: During follow-up, an unfavorable functional outcome was found in 260 patients (35.3%), and 94 patients (12.8%) died. In multivariate models comparing the third and fourth quartiles to the first quartile of FABP4, the concentrations of FABP4 were associated with poor functional outcome and mortality. Compared with the reference category (Q1-Q3), the concentrations of FABP4 in Q4 had a relative risk of 4.77 (95% confidence interval [CI], 2.02-8.15; P<0.001) for poor functional outcome and mortality (odds ratio, 6.15; 95% CI, 3.43-12.68) after adjusting for other significant outcome predictors in univariate logistic regression analysis. Receiver-operating characteristic curves to predict poor functional outcome and mortality demonstrated areas under the curve of FABP4 of 0.78 (95% CI, 0.75-0.82) and 0.83 (95% CI, 0.79-0.88), which improved the prognostic accuracy of National Institutes of Health Stroke Scale score with combined areas under the curve of 0.83 (95% CI, 0.76-0.89; P<0.01) and 0.86 (95% CI, 0.81-0.92), respectively. CONCLUSIONS: Data show that FABP4 is a novel independent prognostic marker improving the currently used risk stratification of stroke patients.
引用
- Tu WJ, Zeng XW, Deng A, et al. Circulating FABP4 (Fatty Acid-Binding Protein 4) Is a Novel Prognostic Biomarker in Patients With Acute Ischemic Stroke. Stroke. 2017. PMID: 28487339. doi:10.1161/STROKEAHA.117.017128
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。